Absci's AI-Designed Antibody ABS-201 Shows Promise, Eli Lilly Backs with $40M
Positive Phase 1 Data for ABS-201 Absci reported positive interim Phase 1 data for ABS-201, its AI-designed antibody for hair loss. The drug was well tolerated with no serious side effects and a long half-life, meaning fewer injections. This raises hopes for future success, pushing the stock up.
This is the core clinical catalyst that drove the stock higher and is new this period.
Eli Lilly's $40 Million Investment Eli Lilly invested $40 million in Absci and will support development of ABS-201. This extends Absci's cash runway into 2028 and signals confidence from a major drugmaker, boosting investor sentiment and the stock price.
This is a new capital event that strengthens Absci's financial position and validates its technology.
Completed $100 Million Stock Offering Absci raised $100 million by selling shares to investors including Eli Lilly. This provides funds to advance ABS-201 and reduces worries about running out of cash, supporting the stock price.
This is a new financing event that removes a financial overhang and funds the pipeline.
Valuation and Financial Risks Despite positive news, Absci's net loss widened to $33.2 million in Q2. The stock trades at a high price-to-book ratio of 9.3x, much higher than the industry average. This could make the stock vulnerable to pullbacks if future data disappoints.
This provides a balanced view of the risks that could limit upside or cause volatility.